Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 6/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.43 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | IL1B | P01584 | 4/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748682 | 0.91 | PRKAB2 (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748528 | 0.78 | PRKAB2 (0.38) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748696 | 0.72 | PRKAB2 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748550 | 0.72 | DGAT1 (0.31) | SYK | |
| SCHEMBL31748621 | 0.70 | SYK (0.30) | SYK | |
| SCHEMBL31748492 | 0.69 | DGAT1 (0.35) | P2RX7MEN1GAAKMT2A | |
| SCHEMBL31748766 | 0.69 | PRKAB2 (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748640 | 0.69 | DGAT1 (0.33) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31748692 | 0.68 | DGAT1 (0.34) | GAA | |
| SCHEMBL31748388 | 0.68 | KLKB1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | PRKAB2 1/4885PRKAG1 6/4885PRKAA2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.